| |
|
|
BREAST
|
|
| |
|
| RAPID NEW |
|
| A randomized trial of accelerated partial breast irradiation: The Canadian RAPID trial. |
|
| |
|
| DDC |
|
| The impact of dose-dense adjuvant chemotherapy (DDC) on body composition, lipid and glucose metabolism, fitness and quality of life in pre-menopausal breast cancer survivors. |
|
| |
|
| ZAMBONEY |
|
| A phase II, multi-centre, randomized, double-blind trial to evaluate the therapeutic benefit of Fulvestrant in combination with ZACTIMA or Fulvestrant plus placebo in postmenopausal women with bone-only or bone-predominant hormone receptor positive metastatic breast cancer. |
|
| |
|
| THORN |
|
| The Hamilton prospective pilot study to investigate the feasibility and safety of a dedicated high resolution nuclear breast imaging camera |
|
| |
|
| MA.31 |
|
| A randomized, open-label, phase III study of Taxane-based chemotherapy with Lapatinib or Trastuzumab as first-line therapy for women with her2/neu positive metastatic breast cancer |
|
| |
|
|
Top
|
|
|
GASTROINTESTINAL
|
|
| |
|
| QL Esophagus |
|
| Predictive indicators and corrective interventions for quality of life in patients with esophageal cancer receiving high dose rate intraluminal brachytherapy using a varisource afterloader. |
|
| |
|
| HDR & PDT |
|
| High dose rate intraluminal brachytherapy and photodynamic therapy in advanced recurrent non-small cell lung cancer and esophageal cancer: Biopsy collection pre-, peri- and post-treatment. |
|
| |
|
| Pilot study of a 'facilitated referral' strategy designed to improve accrual to a a clinical trial for patients with stage III colon cancer |
|
| |
|
| CO 20 |
|
| A phase III randomized study of Brivanib Alaninate (BMS-582664) in combination with Cetuximab (Erbitux) versus placebo in combination with Cetuximab in patients previously treated with combination chemotherapy for metastatic colorectal carcinoma. |
|
| |
|
| GRANITE RAD 0019 |
|
| A randomized, double-blind, multi-centre phase III study comparing Everolimus(Rad001) plus BSC versus placebo plus BSC in patients with advanced gastric cancer after progression on prior systemic chemotherapy |
|
| |
|
| CP20-0801 - OPEN |
|
| An open-label, multicentre, randomized phase II study evaluating the safety and efficacy of 5-Fu/Fa and Oxaliplatin (modified Folfox-6) in combination with Imc-1121b or Imc-18f1 or without investigational therapy as second-line therapy in patients with metastatic colorectal cancer following disease progression on first-line Irinotecan-based therapy. |
|
| |
|
| Top |
|
|
GENITOURINARY
|
|
| |
|
| PROFIT |
|
| A Randomized Trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. |
|
| |
|
| REC.2 |
|
| A randomized, double-blind phase III trial Of adjuvant Sunitinib versus Sorafenib versus Pplacebo in patients with resected renal cell carcinoma. |
|
| |
|
| SPRUCE |
|
| A randomized, placebo-controlled phase II study to compare the efficacy and safety of SU011248 plus best supportive care (BSC) versus placebo plus BSC in patients with advanced urothelial transitional cell carcinoma who have failed or are intolerant to Cisplatin-based chemotherapy. |
|
| |
|
| CAN-ONC-001 (PROSTATE VACCINE STUDY) |
|
| A phase I/II study evaluating the safety and efficacy of vaccination with autologous dendritic cells loaded with synthetic Tn-MUC1 peptide in patients with non-metastatic androgen-independent prostatic adenocarcinoma. |
|
| |
|
| RTOG.0534 |
|
| A phase III trial of short term androgen deprivation with pelvic lymph node or prostate bed-only radiotherapy (Spport) in prostate cancer patients with a rising PSA after radical prostatectomy. |
|
| |
|
| CRCP2 (AFFIRM) |
|
| A multinational, phase III, randomized, double-blind, placebo-controlled efficacy and safety study of oral MDV3100 in patients with progressive castration-resistant prostate cancer previously treated with Docetaxel-based chemotherapy. |
|
| |
|
| OZM-011 |
|
| A randomized phase II efficacy and safety study of Zd6474 Vandetanib in combination with Bicalutamide or Bicalutamide alone in patients with chemo-naive hormone refractory prostate cancer. |
|
| |
|
| Top |
|
|
GYNECOLOGICAL
|
|
| |
|
| PHL.062 - CLOSED |
|
| A phase II study of Sunitinib Malate in recurrent or metastatic endometrial carcinoma. |
|
| |
|
| OV.18 |
|
| A randomized phase III study of concurrent Cediranib (AZD2171) with platinum-based chemotherapy and maintenance Dediranib (AZD2171) in women with platinum-sensitive relapsed ovarian cancer. |
|
| |
|
| IND 192 |
|
| A phase II study of Deforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer. |
|
|
|
| MORAb |
|
| A randomized, double-blind, placebo-controlled study of the efficacy and safety of MORAb-003 (Farletuzumab) in combination with Paclitaxel therapy in subjects with first platinum-resistant or refractory relapsed ovarian cancer. |
|
| |
|
| OSI-906-202 |
|
| A phase I/II study evaluating intermittent and continuous OSI-906 and weekly Paclitaxel in patients with recurrent epithelial ovarian cancer (and other solid tumours). |
|
| |
|
| PHL 072 |
|
| A phase II trial of Temsirolimus and Bevacizumab in patients with endometrial, ovarian, hepatocellular carcinoma, carcinoid or Islet cell cancer |
|
| |
|
| OV.21 |
|
| A phase II/III study of intraperitoneal (IP) plus intravenous (IV) chemotherapy versus IV Carboplatin plus Paclitaxel in patients with epithelial ovarian cancer optimally debulked at surgery following neoadjuvant intravenous chemotherapy. |
|
| |
|
| D0810C000041 - CLOSED |
|
| A phase II, open-label, randomised, comparative, multicentre study to compare the efficacy and tolerability of Olaparib in combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin alone in patients with platinum sensitive advanced serous ovarian cancer. |
|
| |
|
| IND 199 |
|
| The impact of Postitron Emission Tomography (PET) imaging in women with locally advanced cervical cancer. |
|
| |
|
| PET LACE |
|
| The impact of positron emission tomography (PET) imaging in women with locally advanced cervical cancer |
|
| |
|
| Top |
|
|
HEAD & NECK
|
|
| |
|
| Thyroid - CLOSED |
|
| Pilot Study of Thyroid Replacement Therapy for Patients with Subclinical Hypothyroidism Following Radiation Therapy for Cancer of the Head and Neck |
|
| |
|
| A7471027 |
|
| Clinical phase II multicentre trial of PF-00229804 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. |
|
| |
|
| HN.6 |
|
| A phase II study of standard fractionation with concurrent high-dose Cisplatin versus accelerated fractionation radiotherapy with Panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck |
|
| |
|
| POON PET |
|
| The individualization of radical radiation treatment with the use of intra-treatment 2-(F-18) flouro-2-deoxy-d-glucose (FDG) postiron emission tomography in advanced head and neck cancer. |
|
| |
|
| Top |
|
|
HEMATOLOGICAL
|
|
| |
|
| LY.12 |
|
| A phase III Study of gemcitabine, dexamethasone, and cisplatin (GDP) compared to dexamethason, cytarabine, and cisplatin (DHAP) as salvage chemotherapy for patients with relapsed or refractory aggressive histology non-Hodgkin’s lymphoma prior to autologous stem cell transplant and followed by maintenance rituximab versus observation. |
|
| |
|
| Investigation of bone mineral density in the lumbar spine and hip of patients who have completed chemotherapy treatment for lymphoma. |
|
| |
|
| CAM0104 |
|
| Alemtuzumab and CHOP chemotherapy for aggressive histology peripheral T-cell lymphomas: A multicentre phase I and II study. (Accapella) |
|
| |
|
| BORDEN 001 |
|
| A phase II study of Ribavirin in refractory or relapsed acute myelocytic leukemia M4 and M5 subtypes |
|
| |
|
| PO5052 (TALL) |
|
| Phase II study of Temozolomide in previously untreated acute myeloid leukemia (AML) patients unsuitable for standard induction therapy exhibiting low mgmt expression (PO502). |
|
| |
|
| CAMN107A2405 |
|
| An open-label, randomized study of Nilotinib vs. standard Imatinib (400/600 mg QD) comparing the kinetics of complete molecular response for CML-CP patients with evidence of persistent leukemia by RQ-PCR. |
|
| |
|
| OCT-1 |
|
| A study investigating the predictive value of intracellular and plasma Imatinib levels in newly diagnosed patients with chronic myeloid leukemia in chronic phase (OCT-1) Sponsor: Ontario Clinical Oncology Group |
|
| |
|
| CC-5013-CLL-009 |
|
| Phase II, multi-center, randomized, double-blind, parallel-group study of the safety and efficacy of different Lenalidomide (Revlimid) dose regimens in subjects with relapsed or refractory B-cell chronic lymphocytic leukemia |
|
| |
|
| CC5013-MM-020 |
|
| A phase III, randomized, open-label, 3-arm study to determine the efficacy and safety of lenalidomide (Revlimid) plus low-dose dexamethasone when given until progressive disease or for 19 four-week cycles iin patients with previously untreated mulitple myeloma who are either 65 years of age or older or not candidates for stem cell transplantation. |
|
| |
|
| CL.3 - OPEN |
|
| A randomized phase II study of three Fludarabine/Antibody combinations for patients with symptomatic previously untreated chronic lymphocytic leukemia. |
|
| |
|
| Top |
|
|
LUNG
|
|
| |
|
| PEARL |
|
| A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Patients with Non-Small Cell Carcinoma of the Lung |
|
| |
|
| EMR 63325-001/START - HOLD |
|
| Stimulating Targeted Antigenic Responses To NSCLC – A multi-center phase III randomized, double-blind placebo-controlled study of the cancer vaccine Stimuvax® (L-BLP25 or BLP25 liposome vaccine) in non-small cell lung cancer (NSCLC) subjects with unresectable stage III disease (A study to determine the effectiveness of Stimuvax) (EMR 63325-001) |
|
| |
|
| IND 183 - HOLD |
|
| A phase II study of Sunitinib (SU11248; NSC 736511) in patients with advanced malignant pleural mesothelioma. |
|
| |
|
| BR 29 |
|
| A double-blind, randomized trial of Cediranib versus placebo in patients receiving Paclitaxel/Carboplatin chemotherapy for the treatment of advanced or metastatic non-small cell lung cancer. |
|
| |
|
| BI 1230.5 |
|
| A randomized, open-label, phase II trial of BI6727 monotherapy and BI6727 in combination with standard dose Pemetrexed compared to Pemetrexed monotherapy in second-line non-small cell lung cancer. |
|
| |
|
| BR 26 |
|
| A double-blind, placebo-controlled randomized trial of pf-804 in patients with incurable stage IIIB/IV non-small cell lung cancer after failure of standard therapy for advanced or metastatic disease. |
|
| |
|
| IND 190 |
|
| A phase I-II trial of MK-0646, a monoclonal antibody against insulin-like growth factor-1 receptor, in combination with Etoposide and Cisplatin in extensive stage small-cell lung cancer. |
|
| |
|
| CA191005 |
|
| A phase I multiple ascending dose study of BMS-754807 in combination with Paclitaxel and Carboplatin in subjects with advanced or metastatic solid tumours. |
|
| |
|
| BR.28 |
|
| A phase III study of concurrent once-daily versus twice-daily radiotherapy: A 2-arm randomized controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer and good performance status. |
|
| |
|
| Top |
|
|
NEUROLOGY
|
|
| |
|
| CE6 |
|
| A randomizedpPhase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients (NCIC CE.6) |
|
| |
|
| BI 1200.36 - CLOSED |
|
| BIBW 292 with or without daily Temozoamide in the treament of patients with recurrent malignant gliomas. |
|
| |
|
| BRACCO #2 |
|
| Phase IV, double-blind, multi-centre, randomized corssover study to compare 0.1mmol/kg of Multihance with 0.1 mmol/kg of Gadovist in magnetic resonance imaging (MRI) of the brain. |
|
| |
|
| CENTRIC / EMD121974-011 |
|
| A phase III, multicentre, open-label, controlled study testing Cilengitide in combination with standard treatment (Temozolomide with concurrent radiation therapy, followed by Temozolamide maintenance therapy) versus standard treatment alone: Cilengitide in subjects with newly diagnosed glioblastoma multiforma and methylated MGMT gene promoter. |
|
| |
|
| CTSU #574 (RTOG 0671) |
|
| A phase III randomized trial of the role of whole brain radiation therapy in addition to radiosurgery in patients with one to three cerebral metastases. |
|
| |
|
| RTOG 0539 |
|
| A phase II trial of observation for low-risk meningiomas and of radiotherapy for intermediate and high-risk meningiomas. |
|
| |
|
| BO21990 |
|
| A randomized, double-blind, placebo-controlled, multicentre phase III trial of Bevacizumab, Temozolimide and radiotherapy, followed by Bevacizumab and Temozolomide versus placebo, Temozolomide and radiotherapy followed by placebo and Temozolomide in patients with newly-diagnosed glioblastoma. |
|
| |
|
| RTOG 0614 |
|
| A randomized, phase III, double-blind, placebo-controlled trial of Memantine for prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy |
|
| |
|
| BRIM 3 |
|
| A randomized, open-label, controlled, multicentre, phase III study in previously untreated patients with unresectable stage IIIc or stage IV melanoma with V600E BRAF mutation receiving RO5185426 or Dacarbazine (NO25026-ROW). |
|
| |
|
| Top |
|
|
OTHER
|
|
| |
|
| SC.20 |
|
| A phase III international randomized trial of single vs multiple fractions for re-irradiation of painful bone metastases. |
|
| |
|
| A0081128 - CLOSED |
|
| A randomized, placebo-controlled trial of the of the efficacy and tolerability of flexiby-dosed Pregabalin in the treatment of cancer-induced bone pain. |
|
| |
|
| PET REC |
|
| Positron emission tomography / computed tomography (PET/CT) for the diagnosis of recurrent cancer: a feasibility study (PETREC)Sponsor: Ontario Clinical Oncology Group |
|
| Top |
|
|
SARCOMA
|
|
| |
|
| CAMN107G2301 |
|
| A phase III randomized, multi-centre study to evaluate the efficacy and safety of Nilotinib versus Imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumours. |
|
| |
|
| Top |
|
|
MELANOMA
|
|
| |
|
| Skin Cancer |
|
| The use of polarization photography in determining skin cancer margins for radiotherapy. |
|
| |
|
| H8K-MC-JZAO |
|
| A randomized, phase III study of Tasisulam administered as an intravenous infusion on day 1 of a 28-day cycle vs. Paclitaxel as second-line treament in patients with mestastatic melanoma |
|
| |
|
| Top |
|
|
PHASE I TRIALS (Also See Specific Disease Sites)
|
|
| |
|
| IND 177 |
|
| A phase IsStudy of AT7519M given twice weekly in patients with advanced incurable malignancy. |
|
| |
|
| OGX-427 |
|
| A phase I study evaluating a second-generation antisense oligonucleotide (OGX-427) that inhibits heat shock protein 27 (Hsp27). |
|
| |
|
| ARRAY 543-103 |
|
| A phase I, open-label, multiple-dose study to assess the safety, tolerability ad effect of food on pharmacokinetics of the ARRY-334543 tablet formulation given on a twice daily oral regimen in patients with advanced solid tumours. |
|
| |
|
| OSI-906-202 |
|
| A phase I/II study evaluating intermittent and continuous OSI-906 and weekly Paclitaxel in patients with recurrent epithelial ovarian cancer (and other solid tumours). |
|
| |
|
| BB1608-101 |
|
| A phase I clinical study of BBI608 in adult patients with advanced solid tumours. |
|
| |
|
| PJC-003 - OPEN |
|
| A phase I study of various administratrion schedules of RO4929097 with multiparameter assessment (biomarkers, pharmoacokinetics, pharmacodynamics) in patients with advanced solid cancers. |
|
| |
|
|
Top
|
|
|
SUPPORTIVE CARE TRIALS
|
|
| |
|
| No current Supportive Care Clinical Trials at the JCC |
|
| |
|
|
Top
|
|
|
CLINICAL STUDIES
|
|
| |
|
| Non-invasive monitoring of hemoglobin saturation in patients undergoing radiation therapy. |
|
| |
|
| Benign and malignant tumors of bone: Can their destructive nature be reversed? |
|
| |
|
| CIPN |
|
| A phase I/II study to examine the accuracy of spinal cord functional MRI in evaluating chemotherapy induced peripheral neuropathy and the efficacy of acupuncture and acupuncture-like transcutaneous nerve stimulator in treating this condition. |
|
| |
|
| Detection of Lung Cancer - a pan-Canadian study - Sponsor: Terry Fox Research Institute |
|
| |
|
| Analysis of Melanoma-Specific Immunity |
|
| |
|
| A study to evaluate radiation-induced biological effects following a computerized tomography (CT) scan in patients who are undergoing treatment planning from radiation therapy. |
|
| |
|
| Top |
|
| |
|
